Integrative transcriptomics and human tibial artery validation identify ADAM12, PDK4, and RUNX1 as peripheral artery disease-associated genes enriched in calcified tibial arteries

IF 2.3 Q3 Medicine
JVS-vascular science Pub Date : 2026-01-01 Epub Date: 2026-07-27 DOI:10.1016/j.jvssci.2026.100434
Snow Adler DO, Jorge RuizdelRio PhD, Brian Eliceiri PhD, Ann C. Gaffey MS, MD
{"title":"Integrative transcriptomics and human tibial artery validation identify ADAM12, PDK4, and RUNX1 as peripheral artery disease-associated genes enriched in calcified tibial arteries","authors":"Snow Adler DO,&nbsp;Jorge RuizdelRio PhD,&nbsp;Brian Eliceiri PhD,&nbsp;Ann C. Gaffey MS, MD","doi":"10.1016/j.jvssci.2026.100434","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Medial arterial calcification of tibial vessels is a major obstacle to limb salvage in peripheral artery disease (PAD), yet the molecular drivers remain poorly defined. We used publicly available transcriptomic data to nominate candidate genes relevant to vascular calcification and then tested those candidates in human tibial arteries and in primary PAD-derived vascular cells.</div></div><div><h3>Methods</h3><div>Differential gene expression was analyzed across publicly available PAD/chronic limb-threatening ischemia (CLTI) transcriptomic datasets, comparing PAD/CLTI tissue to non-PAD controls (limma and DESeq<sup>2</sup> adjusted <em>P</em> &lt; .05, |log<sub>2</sub> fold-change| &gt; 1.5). Candidates were prioritized based on predicted roles in calcification processes in endothelial cells and vascular smooth muscle cells. Expression was validated by quantitative polymerase chain reaction in isolated human tibial arteries harvested from patients with PAD/CLTI undergoing below-the-knee amputations and non-PAD control vessels. Following the preparation of primary PAD-derived endothelial cells and vascular smooth muscle cells, the cells were cultured under high-glucose or osmotic control conditions for 7 days to assess the effects of a hyperglycemic challenge.</div></div><div><h3>Results</h3><div>Analysis of 14 datasets identified 89 differentially expressed genes enriched in inflammatory, osteogenic, and metabolic pathways. Fourteen candidates were selected for validation. Among them, <em>ADAM12</em>, <em>PDK4</em>, and <em>RUNX1</em> were confirmed in PAD tibial arteries as the most relevant candidates from the prespecified panel, consistent with their prioritization from the transcriptomic and literature-guided candidate-selection strategy.</div></div><div><h3>Conclusions</h3><div>A candidate-first translational strategy integrating public transcriptomic prioritization with validation in human tibial arteries confirmed <em>PDK4</em> and <em>RUNX1</em> as significantly upregulated medial arterial calcification-associated genes in PAD tibial arteries, and identified <em>ADAM12</em> as a biologically prioritized candidate showing a concordant but statistically nonsignificant trend in the same direction. Their expression in diseased tissue, together with the absence of acute glucose responsiveness in primary PAD-derived vascular cells, supports a model in which these genes are linked to chronic vascular remodeling rather than transient hyperglycemic signaling. These findings refine the molecular landscape of PAD-associated calcification and establish a focused framework for potential mechanistic studies.</div></div><div><h3>Clinical relevance</h3><div>Tibial medial arterial calcification is a major barrier to limb salvage in patients with peripheral artery disease (PAD)/chronic limb-threatening ischemia because it makes revascularization more difficult and less durable. By validating candidate genes in human tibial arteries and primary PAD-derived vascular cells, this study links diseased tissue biology to pathways that may help explain why some patients develop severe calcification and experience poor clinical outcomes. These findings provide a disease-specific framework for identifying potential biomarkers and therapeutic targets to improve infrapopliteal revascularization outcomes and reduce limb loss.</div></div>","PeriodicalId":74035,"journal":{"name":"JVS-vascular science","volume":"7 ","pages":"Article 100434"},"PeriodicalIF":2.3000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JVS-vascular science","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666350326000271","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Medial arterial calcification of tibial vessels is a major obstacle to limb salvage in peripheral artery disease (PAD), yet the molecular drivers remain poorly defined. We used publicly available transcriptomic data to nominate candidate genes relevant to vascular calcification and then tested those candidates in human tibial arteries and in primary PAD-derived vascular cells.

Methods

Differential gene expression was analyzed across publicly available PAD/chronic limb-threatening ischemia (CLTI) transcriptomic datasets, comparing PAD/CLTI tissue to non-PAD controls (limma and DESeq2 adjusted P < .05, |log2 fold-change| > 1.5). Candidates were prioritized based on predicted roles in calcification processes in endothelial cells and vascular smooth muscle cells. Expression was validated by quantitative polymerase chain reaction in isolated human tibial arteries harvested from patients with PAD/CLTI undergoing below-the-knee amputations and non-PAD control vessels. Following the preparation of primary PAD-derived endothelial cells and vascular smooth muscle cells, the cells were cultured under high-glucose or osmotic control conditions for 7 days to assess the effects of a hyperglycemic challenge.

Results

Analysis of 14 datasets identified 89 differentially expressed genes enriched in inflammatory, osteogenic, and metabolic pathways. Fourteen candidates were selected for validation. Among them, ADAM12, PDK4, and RUNX1 were confirmed in PAD tibial arteries as the most relevant candidates from the prespecified panel, consistent with their prioritization from the transcriptomic and literature-guided candidate-selection strategy.

Conclusions

A candidate-first translational strategy integrating public transcriptomic prioritization with validation in human tibial arteries confirmed PDK4 and RUNX1 as significantly upregulated medial arterial calcification-associated genes in PAD tibial arteries, and identified ADAM12 as a biologically prioritized candidate showing a concordant but statistically nonsignificant trend in the same direction. Their expression in diseased tissue, together with the absence of acute glucose responsiveness in primary PAD-derived vascular cells, supports a model in which these genes are linked to chronic vascular remodeling rather than transient hyperglycemic signaling. These findings refine the molecular landscape of PAD-associated calcification and establish a focused framework for potential mechanistic studies.

Clinical relevance

Tibial medial arterial calcification is a major barrier to limb salvage in patients with peripheral artery disease (PAD)/chronic limb-threatening ischemia because it makes revascularization more difficult and less durable. By validating candidate genes in human tibial arteries and primary PAD-derived vascular cells, this study links diseased tissue biology to pathways that may help explain why some patients develop severe calcification and experience poor clinical outcomes. These findings provide a disease-specific framework for identifying potential biomarkers and therapeutic targets to improve infrapopliteal revascularization outcomes and reduce limb loss.
整合转录组学和人类胫骨动脉验证鉴定ADAM12、PDK4和RUNX1是钙化胫骨动脉中富集的外周动脉疾病相关基因
背景:胫骨血管内侧动脉钙化是外周动脉疾病(PAD)残肢修复的主要障碍,但其分子驱动因素尚不明确。我们使用公开可用的转录组学数据来指定与血管钙化相关的候选基因,然后在人胫骨动脉和原代pad来源的血管细胞中测试这些候选基因。方法分析公开可用的PAD/慢性肢体威胁缺血(CLTI)转录组数据集的差异基因表达,将PAD/CLTI组织与非PAD对照组进行比较(limma和DESeq2调整P <; 0.05, |log2倍变化| >; 1.5)。候选药物在内皮细胞和血管平滑肌细胞钙化过程中的预测作用被优先考虑。通过定量聚合酶链反应,在接受膝下截肢的PAD/CLTI患者和非PAD对照血管中分离的人胫骨动脉中验证了表达。在制备原代pad来源的内皮细胞和血管平滑肌细胞后,将细胞在高糖或渗透控制条件下培养7天,以评估高血糖刺激的影响。结果对14个数据集的分析确定了89个在炎症、成骨和代谢途径中富集的差异表达基因。选取14个候选者进行验证。其中,ADAM12、PDK4和RUNX1在PAD胫骨动脉中被确认为预先指定的小组中最相关的候选者,这与转录组学和文献指导的候选者选择策略中的优先级一致。结论结合公共转录组优先性和人类胫骨动脉验证的候选优先翻译策略证实PDK4和RUNX1在PAD胫骨动脉中是显著上调的内侧动脉钙化相关基因,并确定ADAM12是生物学上优先的候选基因,在同一方向上表现出一致但统计学上不显著的趋势。它们在病变组织中的表达,以及原发性pad衍生血管细胞中缺乏急性葡萄糖反应性,支持了一种模型,即这些基因与慢性血管重塑有关,而不是与短暂的高血糖信号传导有关。这些发现完善了pad相关钙化的分子景观,并为潜在的机制研究建立了一个重点框架。胫骨内侧动脉钙化是外周动脉疾病(PAD)/慢性肢体威胁缺血患者保留肢体的主要障碍,因为它使血运重建更加困难且不持久。通过验证人类胫骨动脉和原发性pad衍生血管细胞中的候选基因,本研究将病变组织生物学与可能有助于解释为什么一些患者发生严重钙化并经历不良临床结果的途径联系起来。这些发现为确定潜在的生物标志物和治疗靶点提供了一个疾病特异性框架,以改善腘窝下血运重建的结果和减少肢体丧失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
0
审稿时长
28 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书